Comparative Effectiveness of Treatment Options for Plantar Heel Pain: A Systematic Review with Network Meta-Analysis by Babatunde, OO et al.




The Comparative Effectiveness 
of Treatment Options for Plantar 
Heel Pain: A Systematic Review 
with Network Meta-Analysis  
Opeyemi O. Babatunde1, Amardeep Legha1,2, Chris Littlewood1, Linda S 
Chesterton1, Martin J. Thomas1,3, Hylton B. Menz1,4, Danielle A. van der 






Competing interests: None to declare 
 
Author Affiliation and Address: 
 
1Arthritis Research UK Primary Care Centre                                                                                                                
Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, ST5 5BG, United Kingdom 
2Centre for Prognosis Research, Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, 
ST5 5BG, United Kingdom 
3Haywood Academic Rheumatology Centre, Staffordshire and Stoke-on-Trent Partnership NHS Trust, Haywood 
Hospital, Burslem, Staffordshire, ST6 7AG, United Kingdom 
4School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora Victoria, Australia. 
 
Corresponding Author:    Opeyemi Babatunde 
Arthritis Research UK Primary Care Centre 
Research Institute for Primary Care & Health Sciences, Keele University 
Staffordshire, ST5 5BG 
o.babatunde@keele.ac.uk  










Objective: To evaluate the comparative effectiveness of current treatment options for plantar heel pain (PHP).  
Design: Systematic review and network meta-analysis (NMA). 
Data Sources: Medline, EMBASE, CINAHL, AMED, PEDro, Cochrane Database, Web of Science, and WHO 
Clinical Trials Platform were searched from their inception until January 2018. 
Study selection: Randomised controlled trials (RCTs) of adults with PHP investigating common treatments (i.e. 
corticosteroid injection, nonsteroidal anti-inflammatory drugs (NSAIDs), therapeutic exercise, orthoses and/or 
extracorporeal shockwave therapy (ESWT)) compared with each other or a no treatment, placebo/sham control.  
Data extraction and analysis: Data were extracted and checked for accuracy and completeness by pairs of 
reviewers. Primary outcomes were pain and function. Comparative treatment effects were analysed by random 
effects network meta-analysis in the short, medium, and long term. Relative ranking of treatments was assessed 
by surface under the cumulative ranking (SUCRA) probabilities (0-100 scale).  
Results: Thirty-one RCTs (total n= 2450 patients) were included. There was no evidence of inconsistency 
detected between direct and indirect treatment comparisons in the networks, but sparse data led to frequently wide 
confidence intervals. Available evidence does not suggest that any of the commonly used treatments for the 
management of PHP are better than any other, although corticosteroid injections, alone or in combination with 
exercise, and ESWT were ranked most likely to be effective for the management of short, medium and long term 
pain or function; Placebo/sham/control appeared least likely to be effective; and exercise appeared to only be 
beneficial for long term pain or function.  
Conclusions: Current evidence is equivocal regarding which treatment is the most effective for the management 
of PHP. Given limited understanding of long-term effects, there is need for large, methodologically robust 
multicentre RCTs investigating and directly comparing commonly used treatments for the management of PHP. 
Systematic review registration: PROSPERO CRD42016046963.  
 
  








What is already known about the management of plantar heel pain 
 Existing pairwise meta-analyses are limited to comparisons of two or three treatment options for plantar heel 
pain. 
 Clinical decision making regarding the best treatment option is often difficult. 
 
What this study adds 
 For the management of plantar heel pain, available evidence does not support the superiority of any of the 
commonly available treatments over another.   
 However, corticosteroid injections, alone or in combination with exercise, and ESWT appear more likely to 
be effective for relieving plantar heel pain and improving function compared to other treatments in the short, 
medium and long term. 
 Control treatments (which include over the counter pain medications and watchful waiting, as well as placebo 
interventions) generally show less beneficial effects than other treatments for patients with plantar heel pain.  
 The review highlights the need for large high-quality RCTs of the commonly used interventions for the 
management of plantar heel pain.  





Plantar heel pain (PHP) is the most prevalent soft tissue foot complaint, affecting 10% of adults during their 
lifetime1 and accounting for 25% of all foot disorders in athletes.2 Characterised by insidious onset, localised pain 
in the plantar heel region which may extend to the medial arch of the foot, the cause of PHP is unclear but is likely 
multifactorial.  Risk factors include obesity, pronated foot type, reduced ankle or first metatarsophalangeal joint 
range of motion, and prolonged weight-bearing.3-5 PHP reduces mobility, impairs foot and physical function and 
the capacity for work, all of which have a negative impact on health-related quality of life.1 6 7   
In terms of primary care management, current guidance suggests a period of watchful waiting with self-
management advice followed by conservative interventions if there is no improvement, including; therapist-led 
exercises, foot orthoses, corticosteroid injections, and extracorporeal shockwave therapy (ESWT).8-10 Although 
PHP is commonly thought to be a self-limiting condition, resolution of symptoms in some patients may take up 
to 18 months.11 Research to date suggests treatments do offer potential benefits in terms of reduced pain and 
improved function,1 but clinical decision-making is hampered due to a lack of robust evidence to inform the choice 
of treatment.  
A Cochrane systematic review12 considered a range of interventions (including exercises, foot orthoses, 
corticosteroid injections, ESWT, laser therapy and therapeutic ultrasound) for PHP, but was not able to pool the 
available data, found inconclusive evidence for the effectiveness of treatments and overall, found limited evidence 
to inform clinical practice. Since the publication of this review, a number of additional randomised controlled 
trials (RCTs) have been conducted, of which the evidence has yet to be synthesised. A recent review13 of 
conservative treatments for PHP included many interventions (e.g., laser therapy, orthoses, pulsed radiofrequency, 
dry-needling) which are not commonly used for managing PHP, and analyses were limited by lack of power (2-3 
studies, mostly small sample sizes) except for the ESWT vs. placebo comparison. Also, other previous systematic 
reviews10 12 14-16 have focussed mostly on pair-wise comparisons of two or three treatment options. 
Day to day clinical decision making, however, often involves consideration of the “most effective” among 
available treatment options for plantar heel pain. Network meta-analysis (NMA) as a novel synthesis of evidence 
allows for simultaneous inferences regarding clinical effectiveness of all available treatment options, by drawing 
together evidence from direct and indirect comparisons of multiple treatments.17 Compared to traditional pairwise 
comparisons, NMA has the potential to increase the precision of the estimates of effects. Also, NMA enables a 
ranking of the different treatments relative to each other and aids clinical/shared decision making for clinicians 
and patients who may desire to know the “best treatment” on average.17  
There is a need therefore, to undertake a comprehensive, up to date systematic review of the comparative 
effectiveness of treatment options for PHP. Using a network meta-analysis, this study aimed to evaluate and 
compare the most common conservative treatment options for the management of PHP.  
 
The specific objectives of this study were to:  




i. determine the comparative effectiveness of treatments for relieving pain and improving function in 
patients with PHP 
ii. identify gaps in the available evidence, as well as identify promising treatments that require investigation 
in future RCTs. 
METHODS 
Protocol / protocol registration: This review was conducted and reported in accordance with the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension statement for systematic 
reviews incorporating network meta-analyses for healthcare.18 An a priori protocol was established for this review 
and registered with the international prospective register of systematic reviews, PROSPERO number 
CRD42016046963 ( http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016046963).  
Patient involvement: Patient involvement was central to the development of the research question. Within an 
advisory workshop which included participants who currently have or have experienced PHP (n=6) and clinicians 
(n=12; physiotherapists and podiatrists) involved in the management of foot pain, patients discussed their 
experiences of PHP and their concerns about the need to determine effective treatment options for relieving 
symptoms and improving function (i.e. pain free walking).   
Study eligibility: We evaluated each identified RCT against the following predetermined selection criteria: 
(i) Study population: adults, 18 years and older with PHP (including plantar fasciitis, plantar fasciopathy, 
plantar fasciosis) as diagnosed by clinical examination and/or diagnostic imaging.  
(ii) Interventions: The review focussed on four therapeutic interventions (i.e. exercise therapy, corticosteroid 
injections, nonsteroidal anti-inflammatory drugs (NSAIDs), and orthoses) that are commonly used in the 
management of PHP in the UK19 and an additional treatment (i.e. ESWT) which is commonly reported 
in the literature. 
Due to an envisaged lack of suitable data on dosage and procedural variations of treatment options, this 
systematic review and NMA focussed primarily on comparisons of the specified core therapeutic 
interventions (exercise therapy, corticosteroid injections, orthoses, NSAIDs, and ESWT).  
(iii) Comparator: direct comparisons between any of the five core therapeutic interventions (i.e. exercise 
therapy, corticosteroid injections, NSAIDs, orthoses, and ESWT) or comparisons with usual 
care/placebo/sham for PHP in any healthcare setting (community, primary healthcare, or secondary 
healthcare), and without restrictions regarding duration, frequency or intensity of treatment. Studies only 
comparing different procedural techniques of the same intervention (e.g. focal vs radial shockwave) were 
excluded. 
(iv) Outcome measure: the primary outcomes for this review were pain and functional disability. In order to 
be eligible for inclusion, assessment of pain and /or functional disability was required, studies with less 
than 24 hours follow up were excluded. Pain measures were placed in a hierarchy as follows: first step 
pain, pain in the morning, pain on activity (e.g. walking), overall pain (or other measures of pain). This 
hierarchy was used to analyse the most clinically relevant data when multiple pain outcomes were 
reported in a RCT. 




Information sources and search strategy: A comprehensive search strategy was developed in collaboration with 
an information specialist, with input from clinicians and academics in the review team. Eight electronic databases 
(Medline, EMBASE, CINAHL, AMED, PEDro, Cochrane Database of Systematic Reviews Cochrane Controlled 
Clinical Trials [CENTRAL], Web of Science, and WHO International Clinical Trials Registry Platform) were 
searched from their inception until January 2018 (see Appendix 1 for full search strategies). No language 
restrictions were applied. The bibliographies of relevant review articles and selected articles were examined for 
additional potentially relevant trials. 
Study selection: In pairs, reviewers (OB, AL, CL, LSC, MJT, DvdW, ER) independently evaluated the eligibility 
of identified trials. At each stage of titles, abstracts and full texts selection, discrepancies were resolved through 
discussion between pairs of reviewers or via consensus in review team meetings. 
Risk of bias assessment: The Cochrane Collaboration’s Risk of Bias tool20 was used to assess the quality of 
included trials. Trials were graded (unclear, high or low risk of bias) based on: (i) sequence generation, (ii) 
allocation concealment, (iii) blinding of personnel, (iv) blinding of outcome assessor, (v) incomplete outcome 
data, (vi) selective outcome reporting, and (vii) other bias. For each study, risk of bias items was judged as unclear 
when there was either insufficient information to judge as (low/high risk) or there was no related information 
regarding the risk of bias item in the report (further details on risk of bias assessment are presented in Appendix 
1). 
Data extraction: Using a customised, pre-tested and piloted data extraction form, risk of bias and data extraction 
for each included trial were performed by pairs of reviewers. Differences in quality appraisal and extracted data 
were resolved through discussion between pairs of reviewers and where appropriate, the opinion of other members 
of the review team. For each included trial, details were extracted on: design, sample size, population 
characteristics (e.g. age, diagnosis, duration of heel pain, interventions (professional delivering intervention, dose, 
duration, and number of sessions), and outcome assessment (type of outcome measure, length of follow up, and 
outcome measurements). Studies that provided a point estimate of the outcome together with a measure of 
variability (e.g. a mean and standard deviation), were taken forward for analysis. Where only sample size, median, 
range and/or interquartile range was given, methodology from Wan et al21 was used to calculate the sample mean 
and standard deviation. In instances of missing or incomplete data (for example, lack of measures of variability 
for follow up data), additional information was requested and obtained (where possible) through contacting 
primary study authors.  
Data synthesis and analysis 
All analyses were performed using STATA V.15.1 (Stata Corporation, TX, USA), under a frequentist approach, 
with restricted maximum likelihood used to estimate parameters. Prior to analyses, extracted data were further 
checked independently for completion and accuracy by the study statistician while profiling a database for the 
analyses. Furthermore, in order to define the treatment nodes for the network; two reviewers (HBM and ER), a 
podiatrist and rheumatologist, independently reviewed and classified the therapeutic interventions following a 
consensus process. As the objective of this systematic review was to compare different treatment options, and not 
to investigate the influence of dosage or intensity of interventions, the specified core therapeutic interventions 




(exercise therapy, corticosteroid injections, orthoses, NSAIDs, and ESWT), and usual care/placebo/sham, were 
allocated to six distinct nodes. Furthermore, studies involving combination(s) of any of the specified core 
treatments were used in our analyses in addition to the six nodes as treatment nodes with combination treatments. 
For example, where trial arms have involved a combination of exercise therapy and a corticosteroid injection as 
an intervention, corticosteroid injection + exercise was classed as a distinct treatment node. Also, where RCTs 
included more than one arm with the same type of treatment, the data was pooled together (e.g. for a three-armed 
trial22 involving a prefabricated orthoses arm, and two custom orthoses arms (differentiated by a rigid and soft 
material), an average of the mean outcomes and standard deviations was taken from the custom orthoses arms, 
and a sum taken from the arm sample sizes, in order to create a single pooled orthoses arm).  
In order to obtain direct treatment effect estimates (with a 95% confidence interval [CI]) for each included 
comparison pairwise meta-analyses were performed. Direct and indirect estimates of effects were then analysed 
together in a NMA. 
Network coherence (consistency and heterogeneity): The important assumption underlying a NMA is that of 
network consistency; that is, true treatment effects are on average the same, regardless of whether they are 
estimated from direct or indirect evidence. This was assessed in three ways: (i) using a global Wald test (with high 
p-values favouring consistency);23 (ii) using a node-splitting technique which judges the consistency of direct and 
indirect estimates separately for each treatment comparison (with high p-values favouring consistency);24 and (iii) 
graphically (as a crude test), by inspection of forest plots comparing direct and pooled NMA results. Furthermore, 
the choice of a random or fixed effects model for each analysis was based on the magnitude of τ2 (i.e. the common 
between-study variance across all treatment comparisons). A structured between-studies variance-covariance 
matrix was used, which assumes that all treatment comparisons have a common heterogeneity variance. 
Primary outcomes of pain and function were classified as: (i) short term (1 to ≤ 6 weeks post treatment), (ii) 
medium term (6 to ≤ 12 weeks post treatment), or (iii) long term (> 12 weeks post treatment). For short and 
medium term outcomes, the latest outcome data within each time-category was used for analysis. For example, if 
a study reported 3 and 6-week pain outcomes, only the 6-week data were used. However, because the long term 
category has no upper bound, a different approach was taken to reduce potential heterogeneity in results; we 
evaluated the spread of long term outcomes and selected the most prevalent time-point, and only retained data 
matching this time point for analysis. A total of six NMAs were possible (pain or function outcomes analysed 
separately for each time-category), and a network plot was used to graphically present the direct evidence base 
and assess connectedness of each network.   
Assessing comparative effectiveness of treatments: The principal summary measure used for pain and function 
outcomes was the standardised mean difference (SMD). SMDs are advantageous in homogenising outcomes from 
different scales and instruments onto a common scale. The direction of outcome scales in the raw data were 
reversed where appropriate (by multiplying values by -1), to ensure all outcomes were interpreted with lower 
values indicative of improvements in pain or functional disability. Estimates of effects (SMDs) were interpreted 
according to Cohen’s rule of thumb, with values of 0.2, 0.5, and 0.8 indicative of small, moderate, and large 
effects, respectively25. Direct pairwise (where available) and pooled NMA estimates, along with 95% CIs, are 




reported for all treatment comparisons. SMDs with 95% CIs that did not include the null value (of SMD=0, i.e. 
no difference in comparative treatment effect), were classed as statistically significant.  
Ranking of treatments: To further assess the comparative effectiveness of treatments, the ranking probability 
distributions of each treatment were generated from a simulation of 1000 replications. We used mean rank, surface 
under cumulative ranking curve (SUCRA) values, and cumulative ranking plots. These statistics rank treatments 
according to their ability to generate the largest treatment effects in each simulation, and are averaged over the 
1000 replications. 
Sensitivity analysis: To assess the robustness of the findings for pain and functional outcomes, sensitivity analysis 
based on risk of bias was planned but not performed. This was due to most studies showing similar (unclear) risks 
of bias. Sensitivity analysis by the removal of studies with unclear risk led to insufficient data to support the 
network.  
RESULTS 
Characteristics of included studies: The literature search yielded 1400 unique citations, of which 263 full-text 
articles were selected for full review. The study flow chart is presented in Fig.1. Of the 263 full text articles, 59 
met the inclusion criteria and were subjected to quality assessment and data extraction. A further 28 articles could 
not be included in the network meta-analysis due to: being duplicate reports of the same RCT (n=1); examining 
dose regimen/technique comparisons of the same intervention (n=9); examining a similar but different treatment 
to commonly used interventions for PHP i.e., intracorporeal pneumatic shock therapy (n=1); and data/reporting 
problems where authors could not be contacted or failed to respond to queries after repeated attempts over a 3 
month period (n= 17). Summary of findings and the characteristics of eligible studies that could not be 
incorporated into the meta-analysis are presented in Appendix 2 (Tables 1 & 2).  
Thirty-one RCTs involving 2450 participants across ten different (combinations of) interventions (ESWT, ESWT 
+ exercise, ESWT + orthoses, exercise, NSAID injection + exercise, oral NSAIDs, orthoses, corticosteroid 
injection, corticosteroid injection + exercise, and placebo/sham) provided sufficient data for inclusion in the 
NMA. Table 1 (Appendix 1) presents the characteristics of the included RCTs. RCTs were published between 
1999 and 2017. The maximum length of follow up ranged from 4 weeks to 104 weeks. Most RCTs were from 
Europe (n=8), followed by Asia (n=6) and Australia (n=5). RCTs recruited participants mostly from primary care 
sources and outpatient departments of hospitals and rehabilitation centres and investigated a combination of 
participants with duration of PHP symptoms ranging from 10 to 287 weeks. 
Risk of bias in the evidence base  
The risk of bias assessment for the 31 included trials is presented in Fig.2a and 2b. All included studies were 
RCTs, however a significant proportion (35%) did not adequately report how randomisation was performed.  High 
risk of bias was considered present most frequently (in 26% of trials) in relation to lack of blinding of participants 
and personnel. Many of the trial outcomes were patient reported but outcome assessment procedures were reported 
as blinded in 45% of the trials. The reporting of most of the trials did not provide sufficient information to 




accurately assess concealment of treatment allocation, thus generating a large proportion of “unclear” responses 
(61% of trials).  Overall, fourteen 22 26-38 of the 31 trials were considered to be of low quality with fewer than 50% 
of risk of bias items (i.e. ≤ 3/7) classed as low risk. 
Network coherence (consistency and heterogeneity) 
NMA was possible for all (six) connected networks of evidence, which investigated pain and function outcomes 
separately, with follow-ups at: (i) short term, (ii) medium term, and (iii) long term. There were no signs of the 
consistency assumption being violated for any network (where applicable; i.e. only considering closed loop 
networks). Firstly, the global Wald tests for inconsistency were not significant (p = 0.822, 0.971, and 0.925 for 
short term pain, medium term pain, and short term function, respectively). Secondly, no statistically significant 
difference was observed between direct and indirect estimates when assessed separately for each treatment 
comparison through a node-splitting technique (all p values were >0.05). Thirdly, the 95% confidence intervals 
of the network and pairwise meta-analysis summary results overlapped for all three closed loop networks (Fig.1S). 
The heterogeneity term, τ2, was ‘moderate’ to ‘large’ in magnitude (as classed by Cohen’s rule of thumb25) for all 
of the networks except long term function (Appendix 1, Table 2). Hence, random effects analyses were used for 
all but the long term function network (whereby fixed effects analyses were used). Full raw outcome data used 
(including outcome scales) are provided in Appendix 1, Table 3.  
Treatments for PHP: Pain outcomes 
Evidence base: There were 22 studies22 26-28 30 31 33 37 39-53 (21x two-arm, 1x 3-arm) in the short term pain evidence 
base, with a similar sized network of 23 studies27-32 34 37 39-42 44-47 49-56 (22x two-arm, 1x 3-arm) in the medium term, 
and a smaller network of 10 studies29 34-38 40 44 45 49 55 (all two-arm) in the long term; as presented in Fig.3. Eight 
different treatment nodes were used in the short term analysis, with these same treatments and the addition of a 
ninth (ESWT+ exercise) used in the medium term, and eight treatments in the long term. Placebo/sham-ESWT 
comparisons were most prevalent across all pain outcome networks (n=6 studies in short and medium term, n=4 
in long term), and the number of participants ranged from 31 (NSAID injection + exercise in long term) to 574 
(ESWT in medium term). Direct evidence was available for 12 out of a possible 28 pairwise comparisons in the 
short term, 12/36 in the medium term, and 7/28 in the long term. Outcome follow up ranged from 2-6 weeks in 
the short term (n=1,744 total participants used), 2-3 months in the medium term (n=2,018), and was fixed at 12 
months for the long term (n=778).  
Comparative effectiveness of treatments: Full pairwise and network analyses results for pain are presented in 
Table 1. Across both pairwise and network analyses, corticosteroid injection demonstrated a statistically 
significant larger reduction in short term pain over oral NSAIDs (SMD 2.60, 95% CI (0.81, 4.39)); and 
corticosteroid injection combined with exercise showed a statistically significant larger reduction in pain 
compared to exercise alone (SMD 1.20, 95% CI (0.14, 2.26)). Compared to other treatments, oral NSAIDs were 
most often associated with the least statistically significantly reductions in short term pain (by SMD 2.25, 95% 
CI (0.18, 4.33) compared to orthoses, and by SMD 2.61, 95% CI (0.13, 5.09) compared to corticosteroid injection 
combined with exercise).  




Most treatments were not statistically significantly superior to one another and underlying estimates of effect 
presented with very wide confidence intervals. For instance, the network comparison of ESWT combined with 
orthoses showed a non-statistically significant reduction in medium term pain compared to ESWT in combination 
with exercise (SMD=2.36, 95% CI, (-2.17, 6.89)). 
With the highest SUCRA values of 79.5 and 74.4, and the best mean ranks of 2.4 and 2.8, corticosteroid injection 
alone and in combination with exercise ranked amongst the three most effective treatments for short term pain, 
82.7% and 65.7% of the time, respectively (Fig.4A, Table 2). In contrast, oral NSAIDs (which ranked amongst 
the three least effective treatments 97.3% of the time), exercise alone, and placebo/sham interventions 
demonstrated the least comparative effectiveness for pain relief in the short term. General trends from the NMA 
and direct comparisons for medium term pain indicated that ESWT combined with orthoses may be more effective 
than other treatments (highest SUCRA value of 80.3; Fig 4B, Table 2). Oral NSAIDs, exercise, and exercise 
combined with ESWT were least likely to have beneficial effects for the treatment of pain due to PHP in the 
medium term compared to other treatments. Whilst placebo and orthoses appeared least likely to be beneficial for 
long term pain (85.7% and 81.0% of the time ranking amongst three least effective treatments respectively; Fig 
4C, Table 2), superiority of one treatment over another for the remaining six treatments was less clear, with most 
of these treatments having similar rankings (average SUCRA of 60.8).  
Treatments for PHP: Function outcomes 
Evidence base: For function outcomes, there were fewer RCTs available for analysis compared to the pain (14 
studies were in the network for short term function26 30 33 37 39 41-46 48 49 52-53, 11 for medium term30 37 41 42 44-46 49 52-53 
55, and 5 for long term 35 37 44 45 49 55; all two-armed), as shown in Fig.5. Similar treatment nodes were used across 
the networks, with the same six used in short and medium term function analyses (ESWT, ESWT + exercise, 
orthoses, placebo, corticosteroid injection with and without exercise), whilst the long term analysis did not contain 
corticosteroid without exercise. Placebo/sham-ESWT comparisons were most common in the short (n=4 studies) 
and long term (n=2 studies), whilst ESWT/corticosteroid injection and corticosteroid injection with 
exercise/exercise alone comparisons (n=3 studies) were joint most common for medium term. The number of 
participants ranged from 20 (exercise in long term) to 226 (ESWT in short term), and direct evidence was available 
for 7 out of a possible 15, 5/15, and 4/10 comparisons, in the short, medium and long term, respectively. Outcome 
follow up ranged from 2-6 weeks in the short term (n=868 total participants used), 2.5-3 months in the medium 
term (n=811), and was fixed at 12 months for the long term (n=312). 
Comparative effectiveness of treatments:  The comparative effectiveness of treatments (both pairwise and network 
meta-analyses) on function outcomes are presented in Table 3. As with pain outcomes, most treatments were not 
significantly better than one another in the short, medium and long term; confidence intervals were often wide. 
Placebo/sham interventions were comparatively worse at improving functional ability than other treatments; for 
example, network meta-analysis showed statistically significant reductions in long term functional ability (by 
SMD 0.93, 95% CI (0.23, 1.63) compared to corticosteroid injection, by SMD 1.09, 95% CI (0.15, 2.03) compared 
to exercise, and by SMD 0.95, 95% CI (0.50, 1.40) compared to ESWT).  




In agreement with the analyses on pain outcome treatment effects, placebo/sham interventions ranked least likely 
to improve function for patients with PHP (SUCRA values: 16.9, 28.1, and 7.3, in the short, medium, and long 
term respectively; Fig 6 and Table 4), followed by orthoses (SUCRA: 31.8, 42.4, and 19.4, in the short, medium, 
and long term respectively), and exercise alone (SUCRA: 32.2, 29.9 in the short and medium term respectively). 
However, exercise appeared most likely to improve functional ability for long term function (SUCRA: 82.1); 
whilst corticosteroid with and without exercise, and ESWT consistently ranked in the top three treatments most 
likely to improve functional ability.  
Comparison of effectiveness of treatments across pain and function outcomes 
Corticosteroid injection with and without exercise, and ESWT interventions appear most likely to have beneficial 
effects for both pain and function outcomes over all time periods (Fig 7). In contrast, placebo/sham interventions 
appear least likely to improve either pain or function outcomes across all time periods, whilst exercise appears to 
have a non-beneficial effect for short and medium term, but a beneficial effect for long term pain and function. 
Summary of findings for RCTs without suitable data for NMA  
Findings from seventeen RCTs of seven different comparisons and/or treatment combinations, including ESWT 
vs placebo/sham (n=11), exercise vs ESWT (n=1), and custom vs prefabricated orthosis/placebo/sham (n=3), for 
which suitable data could not be obtained are presented in Appendix 2, Table 1. For the comparison between 
ESWT and placebo/sham, with an unclear to high risk of bias across trials, ESWT is reported to be significantly 
more effective than sham/placebo for reducing pain in two out of three trials in the short term, and four out of 
seven in the medium term. There was no evidence for the effect of ESWT on function in the short term but two 
trials reported reduction in functional disability in the medium term.  However, there was uncertainty in evidence 
across trials and time points as shown by very large confidence intervals and inconsistency of the magnitude of 
effects. For both pain and function outcomes and across time points (short, medium and long-term), trials found 
no difference between custom and prefabricated orthoses. All other treatment comparisons/combinations 
contained only one trial with mostly small sample sizes.  
DISCUSSION 
Available evidence does not suggest that any of the commonly used treatments for the management of PHP are 
significantly better than any other, although the results of this NMA show that corticosteroid injections alone or 
in combination with exercise are effective treatments for reducing pain and improving function in the short term. 
However, the magnitude of estimate of effect varied widely across trials with large confidence intervals. 
Furthermore, the overall effect of corticosteroid injections on plantar heel pain is modest, and the potential for 
adverse effects 15 57 such as post-injection steroid-induced increase in pain, fat pad atrophy, nerve injury, and 
rupture of the plantar fascia require careful consideration. There was a greater amount of evidence for ESWT but 
we found no evidence that this treatment confers more beneficial effects (compared to the other treatments in this 
study) for reducing pain and improving function among patients with PHP.  




In the network meta-analyses of both pain and function, placebo/sham interventions and NSAIDs were generally 
shown to be the least effective treatment options. Considering PHP has long been considered to be a self-limiting 
pain condition, our findings indicate that first line management recommendations of PHP with over the counter 
pain medications, NSAIDs and a watchful waiting approach may be sub-optimal. Previous literature has suggested 
that delaying treatment may worsen prognosis, and potentially create a need for further health care use57. The 
findings of this present study supports the notion that access to treatments without a period of watchful waiting 
may be beneficial. 
As the current NMA is the first to examine the comparative effectiveness of the most common treatments for 
PHP, it is difficult to directly compare the findings of the present study with those of previous NMAs which 
examined a limited number of treatments58, or compared dosage/technique for specific treatment options59. 
Previous reviews collectively indicate that exercise and foot orthoses are promising interventions for short and 
medium-term improvements in pain and function60 61. In this review, exercise as a stand-alone treatment was not 
found to consistently confer beneficial effects in reducing pain and improving function for patients with PHP in 
the short-term, but a beneficial effect was found for long term pain and function. There is a lack of evidence 
regarding the most effective exercise dose or delivery method. In this systematic review, included RCTs reported 
varying exercise therapy protocols, dose and regime. As with the review by Almubarak & Foster60, exercise as a 
treatment in this review included stretching and strengthening exercise trials; treatment comparisons including 
exercise in combination with other treatments such as corticosteroid injection mostly had calf stretching as the 
‘exercise’ component. These exercises were mostly home based (apart from the first session that may be 
supervised) and were not individualised or progressed. Within the networks, foot orthoses (prefabricated or 
custom), were not found to be effective as a stand-alone treatment for PHP, but were mostly effective in 
combination with ESWT. Our findings agree with those of recent systematic reviews showing that foot orthoses 
are better than sham/placebo and may be effective for reducing pain in the medium term13 61. 
Study strengths and limitations 
In this study, direct and indirect evidence has been combined in order to assess comparative effectiveness of 
interventions that have not yet (or only minimally) been directly compared in robust high quality trials. There was 
agreement between the direct and indirect evidence which achieved consistency for specified treatments, however 
tests for inconsistency are likely to be underpowered, due to lack of data, as evidenced by wide 95% CIs for 
SMDs. As an alternative to frequentist methods which was used in the current NMA, a Bayesian three-level 
hierarchical NMA model may be employed. This approach has been shown to increase precision of effect 
estimates in meta-analysis of few trials, or a large number of treatment options which can be further sub-divided62. 
However, this approach was deemed to be out of scope for our NMA which mainly focusses on comparisons 
across different treatments. Future NMAs, especially those incorporating dose comparisons and procedural 
variations of the same treatment options, would benefit from Bayesian analysis. 
 
The current study is not without limitations and must be interpreted with caution. First is the inclusion of only the 
most common treatments as opposed to all available treatments for the management of PHP. This decision was 
made in order to inform choice of treatment in primary care settings where PHP patients are mostly seen, and to 




evaluate interventions that are widely available and accessible to patients. Furthermore, networks would likely be 
disconnected when including a large number of treatments evaluated in only a small number of trials. The sparsity 
of data did not allow for a statistical exploration of publication bias, however, we conducted a comprehensive 
search of published and unpublished literature as well as employed a paired screening process to ensure all 
available evidence was identified. However, the findings of this review are still likely to be influenced by the 
small number of trials (mostly with small sample sizes) available to support direct and indirect comparisons in the 
network. For instance, many nodes in the networks (Fig.3 and Fig.5), were connected by only a single trial and 
(for some treatments) with few participants.   
 
The loss of data associated with absence of suitable data for analysis was a challenge in this review. Related first, 
and more importantly, to the disparate reporting of data in scientific reports in this field, a lot of data from 
otherwise eligible (but excluded trials) could not be analysed mostly due to lack of reporting of treatment outcomes 
with a mean as well as a measure of variability. Despite concerted efforts to request this additional data from trial 
authors, the inability of our review to incorporate such data into evidence synthesises inadvertently led to notable 
research waste. As a minimum, for all trials in this field, reporting an average and a measure of variability (e.g. a 
mean and a standard deviation) per trial arm for each follow up period should be required. Furthermore, to avoid 
substantial heterogeneity, data from some trials which used a very different approach to measuring outcomes 
could not be combined in the network. However, this problem could be overcome through the development of 
and adherence to an agreed standardised set of core outcomes to be used in trials in this field. In order to minimise 
the loss of potentially useful evidence, details of all otherwise eligible trials were extracted with a narrative 
summary of findings presented (Appendix 2, Table 1). Generally, the results from these trials were found to be in 
agreement with the evidence presented in the network meta-analysis.  
Implications for clinical practice, policy and future research 
Within the network meta-analysis, control treatments (including placebo/sham interventions, watchful waiting 
approach, over the counter pain medications), and NSAIDs generally showed lack of beneficial effects for patients 
with PHP. For primary care first-point-of-contact decision making purposes, our findings suggest that access to 
treatments may be beneficial for patients with PHP.    
However, findings from this review must be interpreted with caution due to limitations in quality of the evidence 
underpinning the analyses. Of particular concern are predominantly small sample sizes, low quality reporting of 
aspects of study design (especially concealment of treatment allocation), and variability in outcome measures 
across included studies (Appendix 1, Table 3).   Furthermore, this review cannot comment on evidence for 
comparative effectiveness of treatment options where the influence of duration of symptoms prior to treatment 
may be of concern. This is due to the wide variability in the range of duration of symptoms at recruitment across 
studies included in this review and the fact that most trials did not report data regarding the duration of symptoms 
per trial arm. Future research involving patients with PHP should therefore focus on the design of large trials with 
head to head comparisons of active treatments, long term follow-up and higher reporting standards. Furthermore, 
careful consideration of trials investigating the same treatment comparisons (especially for the most promising 




interventions in the short and long term) is an important next step. This will enable exploration of the optimal 
mode of delivery, dosage, and intensity of treatments required for successful management of PHP. 
CONCLUSION 
This is the first NMA to examine the comparative effectiveness of commonly used treatments for PHP and brings 
together available evidence in order to aid evidence-informed clinical decisions in the management of PHP. For 
pain and functional outcomes, most treatments were not significantly better than others in the short, medium and 
long term. The comparative effectiveness of commonly used treatments (i.e. exercise therapy, corticosteroid 
injections, orthoses, NSAIDs, and ESWT) is limited by large variation in magnitude and imprecision of effect 
estimates. Findings indicate the need for large, multicentre trials directly comparing commonly used treatments 
for the management of PHP. 
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Figure 1. Study flow chart 
Figure 2a. Risk of bias for all individual studies (n=31) included in the analysis.  
Figure 2b. Summary of risk of bias across all (n=31) studies included in the analysis. 
(Abbreviations: + (green circle), low risk of bias; ? (amber circle), unclear risk of bias; - (red circle), high risk of bias) 
Figure 3. Network graph of included studies for pain outcomes, with thickness of lines and size of circles 
proportional to number of studies and number of participants, respectively. Shown for: A) short term evidence, 
B) medium term evidence, and C) long term evidence.   
NOTE: black text represents number of studies, and blue text number of participants  
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with 
exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal 
anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or 
customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection 
combined with exercise. 
Figure 4. Cumulative ranking plots to show comparative effectiveness of treatments from a pain outcome 
network meta-analysis, for each of: A) short term outcomes, B) medium term outcomes, and C) long term 
outcomes. Results based on a simulation of 1000 replications.   
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with 
exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal 
anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or 
customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection 
combined with exercise. 
Figure 5. Network graph of included studies for function outcomes, with thickness of lines and size of circles 
proportional to number of studies and number of participants, respectively. Shown for: A) short term evidence, 
B) medium term evidence, and C) long term evidence.   
NOTE: black text represents number of studies, and blue text number of participants  
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, 
Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise. 
Figure 6. Cumulative ranking plots to show comparative effectiveness of treatments from a function outcome 
network meta-analysis, for each of: A) short term outcomes, B) medium term outcomes, and C) long term 
outcomes. Results based on a simulation of 1000 replications.   
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, 
Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise. 
Figure 7. Scatter plots to show comparative effectiveness of treatments*, through surface under cumulative 
ranking curve (SUCRA) values (0-100), for pain (x-axis) and function (y-axis) outcomes. Shown separately for 
each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Note: Higher 
SUCRAs indicate better performing treatments.  
 
 




Note: horizontal and vertical lines added at SUCRA=50 values as a crude guide to identifying comparatively 
better/worse performing treatments for pain/function.    
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, 
Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise. 
* Note that SUCRA results for four treatments are completely omitted, as data was only available for pain, but not function outcomes 
(ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined 
with orthoses, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, and Oral NSAID=oral nonsteroidal anti-
inflammatory drug). 
Figure 1S. Forest plots showing all direct evidence available, as well as pairwise and network meta-analysis 
summary estimates, for each of: A) short term pain outcomes, B) medium term pain outcomes, and C) short 
term function outcomes*.   
Note: blue rectangles and lines represent study level SMDs and 95% CIs respectively (with size of rectangle 
proportional to number of participants), and green and red diamonds represent direct and pooled NMA evidence 
respectively. 
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with 
exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, Oral NSAID=oral nonsteroidal anti-
inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, 
and Steroid Inj+Exe=corticosteroid injection combined with exercise. 
* Note: data from long term pain, medium term function and long term function networks not presented, as all three of these networks were 
open looped, hence direct and pooled NMA evidence were not appropriate to compare. 
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Table 1. Comparative effectiveness results for pain outcome analyses, for each of: A) short term outcomes, B) 
medium term outcomes, and C) long term outcomes.  Summary estimates from the network meta-analysis are 
shown in lower left triangle, and summary estimates from pairwise meta-analysis (i.e. direct evidence) in upper 
right triangle. Each cell shows a standardised mean difference (SMD), with a 95% confidence interval in 
brackets. For any cell, a negative SMD favours the upper-left intervention, and a positive SMD favours the 
lower-right intervention. Significant results in bold text.   
A 
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Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with 
exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal 
anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or 
customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection 
combined with exercise. 
 
Table 2. Network meta-analysis treatment ranking results for pain outcome analyses, for each of: short term 
outcomes, medium term outcomes, and long term outcomes.  Surface under cumulative ranking curve (SUCRA) 
values (0-100) and mean ranks are presented, based on a simulation with 1000 replications. Note: higher 














  SUCRA 
Mean 
Rank 
  SUCRA 
Mean 
Rank 
ESWT 60.7 3.8   67.2 3.6   54.5 4.2 
                  
ESWT+Exe       29.4 6.6   64.2 3.5 
                  
ESWT+Orthoses 66.5 3.3   80.3 2.6       
                  
Exe 24.6 6.3   26.1 6.9   61.4 3.7 
                  
NSAID Inj+Exe             63.3 3.6 
                  
Oral NSAID 3.7 7.7   13.3 7.9       
                  
Orthoses 60.5 3.8   66.6 3.7   20.0 6.6 
                  
Placebo 30.1 5.9   48.7 5.1   15.6 6.9 
                  
Steroid Inj 79.5 2.4   63.7 3.9   58.4 3.9 
                  
Steroid Inj+Exe 74.4 2.8   54.7 4.6   62.7 3.6 
 
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with 
exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal 
anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or 
customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection 
combined with exercise. 




Table 3. Comparative effectiveness results for function outcome analyses, for each of: A) short term outcomes, 
B) medium term outcomes, and C) long term outcomes.  Summary estimates from the network meta-analysis are 
shown in lower left triangle, and summary estimates from pairwise meta-analysis (i.e. direct evidence) in upper 
right triangle. Each cell shows a standardised mean difference (SMD), with a 95% confidence interval in 
brackets. For any cell, a negative SMD favours the upper-left intervention, and a positive SMD favours the 
lower-right intervention. Significant results in bold text.   
A 














































































































































Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, 
Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise. 
  




Table 4. Network meta-analysis treatment ranking results for function outcome analyses, for each of: short term 
outcomes, medium term outcomes, and long term outcomes.  Surface under cumulative ranking curve (SUCRA) 
values (0-100) and mean ranks are presented, based on a simulation with 1000 replications. Note: higher 














  SUCRA 
Mean 
Rank 
  SUCRA 
Mean 
Rank 
ESWT 69.5 2.5   65.6 2.7   72.8 2.1 
                  
Exe 32.2 4.4   29.9 4.5   82.1 1.7 
                  
Orthoses 31.8 4.4   42.4 3.9   19.4 4.2 
                  
Placebo 16.9 5.2   28.1 4.6   7.3 4.7 
                  
Steroid Inj 78.9 2.1   62.7 2.9   68.4 2.3 
                  
Steroid Inj +Exe 70.6 2.5   71.4 2.4       
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, 




























PHP NMA Appendix I 
Search Strategy (run on 31.01.18). RCT Filter: Cochrane Handbook sensitivity and precision maximising 
 
  
EMBASE PubMed  Pedro  
1. (plantar adj3 fasci$).mp. 
2. (heel adj3 pain$).mp. 
3. calcaneodynia.mp. 
4. (plantar adj3 aponeurosis).mp. 
5. (heel adj3 spur$).mp. 





11. cross over$.ti,ab. 
12. placebo$.ti,ab. 
13. (doub$ adj blind$).ti,ab. 




18. double-blind procedure/ 
20. crossover-procedure/ 
21. randomized controlled trial/ 
22. single-blind procedure/ 
23. or/8-21 
24. 7 and 22 
25. exp animal/ not human/ 
26. 23 not 24 
27. limit 25 to embase 
 
 
CINAHL (HDAS) RCT Filter: 
based on Pubmed Cochrane filter 
 
"((((plantar ADJ3 (fasci*).af) OR 
(heel ADJ3 (pain*).af) OR 
(calcaneodynia).af OR (plantar 
ADJ3 (aponeurosis).af) OR (heel 
ADJ3 (spur*).af) OR (calcane* 
ADJ3 (spur*).af)) AND 
(("randomized controlled 
trial").pt OR ("controlled clinical 
trial").af OR (randomized).ti,ab 
OR (placebo).ti,ab OR exp 
CLINICAL TRIALS/ OR 
(randomly).ti,ab OR (trial).ti)) 
NOT (exp ANIMALS/ NOT 
HUMANS/)) 
((((((randomized controlled trial[Publication 
Type]) OR (controlled clinical trial[Publication 
Type]) OR (randomized[Title/Abstract]) OR 
(placebo[Title/Abstract]) OR ("Clinical Trials 
as Topic"[Mesh:noexp]) OR 
(randomly[Title/Abstract]) OR (trial[Title])))) 
AND (((plantar AND fasci*) OR (heel AND 
pain*) OR (calcaneodynia) OR (plantar AND 
aponeurosis) OR (heel AND spur*) OR 




#1 plantar near/3 fasci*   
#2 heel near/3 pain*  
#3 calcaneodynia 
#4 plantar near/3 aponeurosis #5 heel near/3 
spur*   
#6 calcane* near/3 spur*  
#7 #1 or #2 or #3 or #4 or #5 or #6 
AMED (HDAS) RCT Filter: based on Pubmed 
filter 
 
"((((plantar ADJ3 (fasci*).af) OR (heel ADJ3 
(pain*).af) OR (calcaneodynia).af OR (plantar 
ADJ3 (aponeurosis).af) OR (heel ADJ3 
(spur*).af) OR (calcane* ADJ3 (spur*).af)) 
AND (("randomized controlled trial").pt OR 
("controlled clinical trial").pt OR 
(randomized).ti,ab OR (placebo).ti,ab OR exp 
CLINICAL TRIALS/ OR (randomly).ti,ab OR 




Title & Abstract: Plantar fasci*  (selected 
combine terms with AND) 
Title & Abstract: heel pain* (selected 
combine terms with AND) 
Title & Abstract: calcaneodynia (selected 
combine terms with AND) 
Title & Abstract: plantar aponeurosis 
(selected combine terms with AND) 
Title & Abstract: heel spur* (selected 
combine terms with AND) 
Title & Abstract: calcane* spur* (selected 
combine terms with AND) 
Clinicaltrials.gov 
Nb: words in brackets are automatically 
searched as AND 
(plantar fasciitis) OR (plantar fasciopathy) 
OR (plantar fasciosis) OR (heel pain) OR 
(painful heel) OR calcaneodynia OR 
(plantar aponeurosis) OR (heel spur) OR 
(heel spurs) OR (calcaneal spur) OR 
(calcaneal spurs) 
Web of Science (Indexes=SCI-
EXPANDED, SSCI, CPCI-S, CPCI-SSH) 
RCT Filter: based on Pubmed filter 
# 14 #13 AND #7  
# 13 #12 OR #11 OR #10 OR #9 OR #8  
# 12 ti=trial  
# 11 ts=placebo  
# 10 ts=(randomly OR randomized)  
# 9 ts="clinical trial*"  
# 8 ts="randomized controlled trial"  
# 7 #6 OR #5 OR #4 OR #3 OR #2 OR 
#1  
# 6 ts=(calcane* near/3 spur*)  
# 5 ts=(heel near/3 spur*)  
# 4 ts=(plantar near/3 aponeurosis)  
# 3 ts=calcaneodynia  
# 2 ts=(heel near/3 pain*)  
# 1 ts=(plantar near/3 fasci*) 




Notes for using Cochrane Risk of Bias tool  
Random sequence generation 
 High risk if clearly non-random method used, e.g, alternating allocation, or based on a date 
 Unclear if not enough information given to judge 
 Low risk if randomisation method described is appropriate, e.g. computer-generated sequence, or use 
of random number tables to generate sequence 
Allocation concealment 
 High risk if personnel responsible for the selection of trial participants can influence allocation of next 
patient 
 Unclear if not described  
Low risk if appropriate method used such as remote randomisation or sealed, opaque envelopes 
Blinding of participants and personnel 
High risk if neither are blinded 
Unclear if not reported or if only participants OR personnel (e.g. clinicians proving treatment) but not 
both blinded 
Low risk if both are blinded 
Blinding of outcome assessors 
High risk if outcome assessors (or participants if self-reported measure, eg pain) not blinded 
Unclear if not reported 
Low risk if outcome assessors (or participants if self-reported measure, eg pain) are blinded 
Incomplete outcome data 
High risk if >20% dropout rate OR attrition is clearly uneven between groups 
Unclear if not reported 
Low risk if dropouts <20% and attrition similar in groups 
Selective outcome reporting 
High risk if results for outcomes mentioned in methods not reported 
Unclear if results not reported for all outcomes or unsure 
Low risk if results for all outcomes mentioned are reported 
Other sources of bias 
 High risk if any other concerns about validity/conduct of the trial, e.g. baseline imbalance, conflicts of 
interest, issues with treatment adherence, in appropriate ways of dealing with missing values, or other 
methodological issues 
  

























Intervention description and dose 
/ 
No of sessions/ Duration of 
treatment :  
Control/Intervention II 
description and dose / 











<3 months, no prior 
treatment, VAS score 
5-9 in 10cm scale. 
120 41.7 ± 8.87 
38.4 ± 11.63 
<12 Steroid Injection:  
single injection 40 mg (1 ml) 
methylprednisolone and 2 ml of 
0.5% bupivacaine. 
Co-interventions: ice, avoid 
strenuous activity >48 hours, 
stretching exercises after 1 week. 
NSAIDs: oral diclofenae (50 
mg) and paracetamol (500 mg), 
twice daily plus ranitidine (150 
mg) for 4 weeks   
Co-interventions: NR 
NR All: use soft heel foot wear, not 
stand for long time, and not 
walk bare foot. 
Buchbinder 
2002 
Australia Outpatient Plantar fasciitis 
> 6 weeks, ultrasound 
confirmed lesion 
166 52.2 ± 12.81 





3 sessions of 2000/2500 shock 
waves per treatment for 3 weeks. 
Total dose 1000 mJ/mm2. 
Ultrasound gel used.  
Placebo ESWT: 3 sessions of 
100 shock waves per treatment, 





All: allowed to continue to 
wear orthotics/splints as 
prescribed, new orthopaedic 
devices not allowed; only 
paracetamol,  no other therapies 
allowed. 
Chow 2007 Hong 
Kong 
Outpatient Chronic heel pain>3 
months. 
57 51.94 ± 11.68 
50.64 ± 9.75 
40 ESWT: 
3 sessions (1 per wk) of 1000 shock 
wave impulses, 3 Hz. Dose 0.05 mJ/ 
mm2, increasing to highest possible 
tolerable pain level. Ultrasound 
used.   
Placebo ESWT: 
3 sessions (1 per wk) of 30 
shock wave impulses, 3 Hz. 
Dose 0.03 mJ/ mm2. 
Ultrasound used.   
  
NR Maximum tolerable’ energy 
density group, starting density 
0.05 mJ/mm2, increased by a 
‘staircase’ method after every 





Plantat fasciitis > 3 
months; fascia 
thickness 
40 NR Unclear ESWT + Exercise: 
3 sessions (1 per wk) of 2 000 
shock waves at 6Hz and pressure of 
3 bar. 
Stretching exercises as home 
programme 
Exercise: 10 sessions (5 weeks) 
of Physiotherapy incorporating 
Ultrasound (1Hz, intensity 1.2 








Haake 2013 Germany Hospital/Re
habilitation 
Plantar fasciitis with 
proven heel spur, 
failed >6 month 
conservative 
treatment, 4 weeks 
Therapy free period 
before referral 
272 53.1 ± 10.8 
52.9 ± 10.8 
56 ESWT:  
3 sessions (over 6 weeks) ESWT 4 
000 waves under local anaesthesia. 
Dose: 0.08mj/mm2 
Placebo: 3 sessions (over 6 
weeks) of sham ESWT under 
local anaesthesia 
Physician  











Plantar fasciitis; able 
to walk > 50metres 
without support. 
34 Unclear NR ESWT:  
3 sessions (over 3 wks) of 2000 
shockwaves Dose: 0.25mj/mm2 








Iran Outpatient Acute plantar fasciitis 
<6 weeks, VAS>5 
84 43.91 ± 7.96 
44.68 ± 9.2 
NR ESWT: 3 sessions (over 3 wks), 
intermediate shock wave therapy 
(electrohydraulic system) of 2000 
wave impulses at an energy level of 
0.15 mJ/mm2. Dose: 900 mJ/mm2 
Steroid Injections:  
1 mL of methyl prednisolone 
acetate (40 mg) and 1 mL of 
lidocaine 2% 





Australia Community Plantar fasciitis > 8 
weeks duration, 




82 51.7 ± 11.9 
53.6 ± 9 
42 Steroid Injections + exercise:  
intrafascial injection of 1 mL of 4 
mg/mL dexamethasone sodium 
phosphate (following prior 
ultrasound-guided posterior tibial 
nerve block with 
2% lidocaine hydrochloride) 
 
Daily stretching programme for first 
8 weeks. 
Exercise: daily stretching 
programme for 8 weeks 
 
ultrasound-guided injection 
with 1 mL 0.9% sodium 
chloride  and tibial nerve block 
with 2% lidocaine 
hydrochloride. 
Podiatrist No further detail reported about 
the stretching programme. 
Oliveira 
2015 
Brazil Outpatient Plantar fasciitis 
foot pain 3-8 cm on a 
0-10 NRS, age ≥ 18yrs 
74 48 ± 10.1 
53 ± 10.8 
48 Custom orthoses: 
ethylene vinyl acetate Total contact 
insole, for "day-to-day use" for 26 
wks 
Placebo: flat insole for 26 wks NR 
 




Unclear Proximal plantar 
fasciopathy 
Plantar heel pain, 
worse in morning, 
duration at least 6 
weeks 
132 39.9 ± NR 
38.6 ± NR 
11.8 Steroid Injections + ESWT:  
1 ml betamethasone (5.7mg) and 
2ml 1% lignocaine. 
 
3 applications of 1000 pulses of 
energy density 0.08/mm2 
ESWT + exercise: 
3 applications (3wks) of 1000 
pulses of energy density 
0.08/mm2  
 










Australia Community Plantar heel pain >4 
weeks 
92 50.7 ± 11.8 
50.1 ± 11 
56 Exercise:  
Stretching while standing on 
standardised, supplied wedge + 
sham ultrasound session 
5 min/day over 2 weeks 
Placebo:  
sham ultrasound-3mins.  
NR All: Advice not to commence 
any new treatments 
Ryan 2013 Canada Community Chronic plantar 
fasciopathy 
>12 months, >20 on 
100mm VAS for pain.  
56 52.4 ± 7.5 
46.2 ± 8.5 
287  Exercise:  
12 week exercise programme: 
karaoke, balance/ stretching 
Steroid Injections + Exercise:  
palpation guided, cortiosteroid 
injection (1ml dexamethasone 




st Injection by 
 







Co-interventions: In group 2 








Painful heel (unilateral 
and chronic).   
6 months failed 
conservative 
treatment, > 4 weeks 
therapy free period 
before referral. 
50 56.6 ± 2.71 
49.1 ± 2.55 
NR ESWT:  
2 sessions 2,000 impulses (Air 
pressure of device at 3.5 bar) Dose 
=0.16 mJ/mm2; 15 mm applicator at 
frequency of 8 Hz. 
Placebo:  
2 sessions of sham ESWT 
performed with clasp on heel to 
prevent transmission of 




Standardised protocol but PI 
not blinded.  
Kudo 2006 Canada Outpatient Plantar fasciitis > 6 
months, stretching 




(can include NSAIDs), 
RandM scores of >=3 
114 51.1 ± 10.6 
48.8 ± 9.8 
126.4 ESWT: 1 session of 3800 
shockwaves, total energy delivery 
of 1,300 mJ/mm2 (ED+) or 2,330 
mJ/mm2 (ED). 
Placebo: sham ESWT with thin 








Both groups received 5 mL of 
1% Xylocaine (medial 
calcaneal nerve block), 15–20 
min prior to the procedure. 
Landorf 
2006 
Australia Community Plantar fasciitis 
PF symptoms for > 4 
weeks 
136 47.3 ± 11.6 
48.5 ± 9.6 
52 Prefabricated orthoses:  
strong foot support mould made 
from firm density polyethylene 
foam. 
 Custom orthosis: Strong foot 




sham orthosis-minimal foot 
support from soft (120 kg/m3) 
ethyl vinyl acetate foam over 
an unmodified cast of the foot. 
Mahindra 
2016 
India Unclear Chronic heel pain; 
failed >3 months of 
conservative trt  
75 33.92 ± 8.61 
35.48 ± 9.54 
NR Steroid Injections + Exercise:  
 1 Dose 2mL of 40mg of 
methylprednisolone. 
 
Physical therapy to stretch calf and 
PF 
Exercise:  
Physical therapy to stretch calf 
and PF 
 
injection of normal saline 
 
NR Used two out of three 





Unclear Chronic plantar 
fasciitis (unilateral); > 
6 mnth; stretching 
programme in last 6 
mnth; VAS first step 
pain >5; Roles and 
Maudsley 3 or 4; 
unsuccessful 
conservative therapy 
150 50 ± NR 
53 ± NR 
91.5 ESWT: 3800 shocks (3500 at 0.36 
mJ/mm2) for a total of 1300 
mJ/mm2 (generated using the Epos 
Ultradevice. Medial calcaneal nerve 
block using 5 mL of 
1% xylocaine 15–20 minutes prior 
to the procedure). 
Placebo:  
sham ESWT. With  thin air 
cushion on the therapy head 
NR  









Germany Unclear Plantar fasciitis 
(clinical diagnosis 
with MRI) 
30 51.6 ± 12.5 
53.8 ± 13.2 
~10 Custom orthoses:  
Rigid material with a layered, 
polyurethane cushion zone.  
Individualization for each 
Patient was carried out with the 
help of an orthopaedic technician. 
Placebo:  
Thin, non-supportive orthotic, 
made of 
polyethylene (PE) and thin 
polyurethane (PU). Besides 
trimming for 
sizing purposes, no further 
adjustments are possible. 
Orthopaedic 
technician 
 Used two out of three 
interventions in analysis  
No co-interventions allowed 
(all groups) 
Yan 2014 China Unclear Plantar fasciitis 
(clinical diagnosis 
with ultrasound or 
MRI) 
153 NR 94.24+/-39.92 ESWT + custom orthoses: 5 
sessions (1 per wk) 1000-2000 
Shockwave 10-15Hz; pressure-1-4 
bar  
Custom orthoses 
ESWT: 5 sessions (once a 
week) 1000-2000 Shockwave 
10-15Hz; pressure-1-4 bar. 
NR 3rd arm : custom orthoses 
Yucel 2010 unclear Unclear Plantar fasciitis > 
6mnths; unsuccessful 
conservative therapy. 
60 44.7 ± 9.2 
42.9 ± 7.08 
38.6 Steroid Injections:  
0.5 mL combined betamethasone 
dipropionate (6.43 mg/mL) and 
betamethasone sodium phosphate 
(2.63 mg/mL) and 0.5 mL of 
prilocaine hydrochloride, 2% (20 
mg/mL) applied to the most painful 
area over the medial calcaneal 
tuberosity determined by palpation.  
Patients were instructed to refrain 
from running and impact 
activities for 10 days. 
ESWT: Single application of 
3000 shock-waves 
using an electrohydraulic 
shockwave generator. Fivefold 
nerve block was applied with 
20 mL of prilocaine 
hydrochloride, 2%.  
ultrasound gel was used as a 
contact medium. 
NR Except for the continued use of 
heel cups, no additional 
treatment 
was permitted. 
Yucel 2013 Turkey Outpatient Plantar fasciitis 
(unilateral) pain> 3 
months; First-step pain 
>4 (0–10 VAS). 
44 45.6 ± 9.3 
47.4 ± 7.9 
29.2 Steroid Injections:  
Single Ultrasound guided injection 
of 1 mL betamethasone 
dipropionate (6.43mg/ml) and 
betamethasone sodium phosphate 
(2.63 mg/mL) combination plus 1 
mL lidocaine HCl 20 mg/2 mL).  
prefabricated orthoses:  
full-length silicone insole worn 
in daily 
lives for 4 weeks. No change to 
usual diet, daily  activities, and 
sporting habits. 
NR Simple analgesics (such as 
acetaminophen) was allowed if 
necessary, except last 24 h 
before evaluations 
Celik 2016 Turkey Hospital/Re
habilitation 
Plantar fasciitis; a 
negative tarsal tunnel 
test, and a positive 
windlass test. 
43 45.6 ± 7.9 
45.4 ± 9.3 
~48 Steroid Injections: 
1 mL of corticosteroid (40 mg 
methylprednisolone acetate) 
or 4 mL of 2% prilocaine 
hydrochloride was injected using a 
22-gauge needle. 
Exercise: 9 sessions (3 weeks) 




(Stretching for a count of 30 







Exercise group patients were 
advised to repeat the same 
stretching exercises on their 
own. No calf stretches 
performed for injection group. 











Heel pain 106 59.41 ± 11.84 
56.88 ± 13.02 
~24 Steroid Injections:  
1 ml of 25 mg/ml of prednisolone 
acetate with 1 ml of 2% lignocaine 
to medial aspect of the heel pad 
once 
Placebo: 2 ml of 1% lignocaine 





Used two out of four 
interventions in analysis. 
Patients using orthoses, insoles, 
pads or analgesia allowed to 
continue as normal. 
Vahdatpour 
2012 
Iran Outpatient Plantar fasciitis> three 
months, failed 
previous treatments 
40 50.6 ± 10 
48.1 ± 8.9 
NR ESWT: 3 applications (over 3 wks)  
of 2000 focused shock waves and 
2000 radial pulses (4000 shock 
waves/session of 0.2 mJ/mm2). 
Placebo:  
sham ESWT, minimal energy 
pulses (0.04 mJ/ mm2). 
NR Conservative managements 
including stretching exercise, 
using NSAIDs, and heel pad 
were permitted in both groups 




Plantar fasciitis, failed 
conservative treatment 
> 8 weeks  
65 49 ± 12.9 
50.1 ± 10.7 
24 Median Steroid Injections:  
2 Ultrasound guided injection, 0.5 
ml (20 mg) of methylprednisolone 
acetate +0.5 ml of 0.9% saline over 
6 or 12 wks.  
Placebo: ultrasound guided 
injection, 1 ml of 0.9% saline. 











3 arm trial. (3rd arm unguided 
injection dropped from the 
analysis). 
All patients were asked to 
avoid weight bearing on the 
heel pad for 48h and allowed to 
continue usual analgesics 
Lizis 2015 Poland Hospital/
Rehabilita
tion 
Plantar fasciitis (not 
explicitly stated in 
text) 
30 NR NR ESWT: 1000 or 2000 shock 
waves per treatment, energy 
levels varying between 0.02 and 
0.33 mJ/mm2, pulse freq 
gradually increased to 240/min 
over 5 wks. 
Placebo: Sham ESWT of 
100 shock waves per 
treatment, energy level of 





Only long term outcome 
data (12 months) reported 




Turkey? Unclear Plantar fasciitis. 
failed conservative 
treatments > 3 mths 
64 41.4±12. NR NSAIDs: 1 application of Local 
injection of 1 mL of tenoxicam 





Local injection of 1 mL of 
40mg of 
methylprednisolone acetate 




Only long term outcome 
data (6, 12 months) 
reported.  
All arms: limit use of feet 
for ~ 4 weeks. 48 hours post 







Outpatient chronic plantar 
fasciitis 
Moderate-severe 
pain; >12 months, 





3 applications of 2 100 impulses 
of 0.16mJ/mm2, 4Hz radius 
1.5-2cm over 3 wks. 
Placebo:  
3 applications of Sham 
ESWT over 3 wks with 
sound reflecting pad, no 
coupling gel.  
physician Only long term outcome 
data (6, 12 months) 
reported.  








previous 6 months 
Hocaoglu  
2017 
Turkey Outpatient Plantar fasciitis. 
non-response to 
conservative 
treatment for 6 
months 
72 50±8.3 34 ESWT: 
3 applications of 2000 
shockwaves at 10Hz frequency 
with an energy flux density per 
shock of 0.16mJ/mm2 over a 
week period 
Steroid Injections: Single 
dose. 1ml of betamethasone 





Advice to avoid any pain 








failure to respond to 
conservative care 
for 2 months 
40 41.4±8 9.5 ESWT: 5 applications of 2000 
shockwaves at 2 pulses per 
second with an energy flux 
density per shock of 
0.2mJ/mm2 over 2 weeks 
 
Steroid Injections: Single 
dose of 40mg of 
methylprednisolone plus 
1mL of 1% lidocaine 
 












response to previous 
(NSAIDs), 
intramuscular 
steroids and / or 
rehabilitation. 
60 53 (range 26-
72) 
NR ESWT: 
2500 shocks in total per 
application. frequency range of 
6-12 hertz (h). 4 sessions were 
performed in 8 to 10 days 
interval. 
 
Steroid Injections: single 
dose of 3 cc lidocaine 
injections with epinephrine 
plus 2 cc of 
methylprednisolone acetate 




NR Cold pack was given as co-
intervention 
NR: Not reported  







Table 2. Between study variation, τ2, from each type of network meta-analysis.  Presented as mean (95% confidence interval). 
Evidence base τ2; Mean (95% CI) 
Short term pain 0.77 (0.27,1.52) 
Medium term pain 2.02 (0.76,3.9) 
Long term pain 0.64 (0.01,2.23) 
  
Short term function 2.41 (0.61,5.4) 
Medium term function 1.28 (0.18,3.37) 
Long term function 0* 
CI=confidence interval. 
*Note: 95% CI not presented as no heterogeneity present 
  

















  Outcome, Mean (SD)   Outcome Measure 
    Pain Function  Pain Function 
Hocaoglu,  
2017 
  ESWT   1 month   36 36  50.00 (16.55) 124.90 (29.30)  VAS, 4. Overall/others  Total FFI  
 Steroid Inj  1 month  36 36  40.00 (14.19) 78.60 (20.70)  VAS, 4. Overall/others  Total FFI  
 ESWT  3 months  36 36  35.00 (11.82) 67.00 (29.70)  VAS, 4. Overall/others  Total FFI  
  Steroid Inj   3 months   36 36  42.50 (16.55) 57.00 (19.10)  VAS, 4. Overall/others  Total FFI  
Serna,  
2017 
  ESWT   1 month   27 36  2.70 (2.33) -68.52 (41.32)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 Steroid Inj  1 month  16 22  2.12 (1.59) -68.72 (44.08)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 ESWT  3 months  27 36  1.96 (1.91) -71.22 (42.38)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 Steroid Inj  3 months  16 22  1.12 (0.34) -71.27 (44.87)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 ESWT  12 months  25 35  1.68 (1.97) -67.82 (44.37)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 





 Steroid Inj  6 weeks  20 20  1.20 (1.40) -85.70 (11.20)  VAS, 3. Activity  FAAM* 
 Exe  6 weeks  21 21  5.00 (2.30) -70.20 (17.50)  VAS, 3. Activity  FAAM* 
 Steroid Inj  3 months  20 20  1.50 (1.90) -83.50 (14.60)  VAS, 3. Activity  FAAM* 
 Exe  3 months  21 21  4.90 (2.40) -69.40 (16.80)  VAS, 3. Activity  FAAM* 
 Steroid Inj  12 months  19 19  3.30 (3.20) -83.40 (17.30)  VAS, 3. Activity  FAAM* 
 Exe  12 months  20 20  2.70 (3.20) -86.70 (21.90)  VAS, 3. Activity  FAAM* 
Eslamian,  
2016 
  ESWT   6 weeks   20 20  4.80 (0.56) 29.70 (20.83)  VAS, 2. Morning  Total FFI  
 Steroid Inj  6 weeks  20 20  5.40 (0.56) 38.20 (16.27)  VAS, 2. Morning  Total FFI  
 ESWT  10 weeks  20 20  3.40 (0.62) 19.60 (21.26)  VAS, 2. Morning  Total FFI  
 Steroid Inj  10 weeks  20 20  4.60 (0.62) 31.50 (20.53)  VAS, 2. Morning  Total FFI  
Hawamdeh, 
2016 
  ESWT   3 weeks   12 12  2.56 (1.33) 1.56 (0.73)  VAS, 4. Overall/others  R&M  
 Placebo  3 weeks  12 12  4.00 (3.46) 2.08 (1.24)  VAS, 4. Overall/others  R&M  









  Steroid Inj+Exe   3 weeks   25 25  2.84 (1.46) -86.60 (6.77)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 Exe  3 weeks  25 25  7.12 (1.12) -53.88 (11.81)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 
 Steroid Inj+Exe  3 months  25 25  3.64 (1.62) -81.32 (6.39)  VAS, 4. Overall/others  
AOFAS Ankle-Hindfoot 
Scale* 





  ESWT   12 months   16    3.30 (0.80)    VAS, 3. Activity    
 Placebo  12 months  14   4.70 (0.80)   VAS, 3. Activity   
Mardani-Kivi, 
2015 
  ESWT   6 weeks   34    6.40 (3.20)    VAS, 4. Overall/others    
 Steroid Inj  6 weeks  34   2.20 (3.50)   VAS, 4. Overall/others   
 ESWT  3 months  34   6.90 (3.10)   VAS, 4. Overall/others   
 Steroid Inj  3 months  34   3.40 (3.70)   VAS, 4. Overall/others   
Oliveira,  
2015 
  Orthoses   6 weeks   36 36  4.40 (2.40) 31.90 (17.20)  VAS, 3. Activity  Total FFI  
 Placebo  6 weeks  36 36  4.30 (3.00) 37.20 (17.70)  VAS, 3. Activity  Total FFI  
 Orthoses  3 months  35 35  3.50 (2.70) 27.00 (17.30)  VAS, 3. Activity  Total FFI  
 Placebo  3 months  35 35  4.20 (3.20) 34.70 (21.30)  VAS, 3. Activity  Total FFI  
Ryan,  
2014 
  Exe   6 weeks   28 28  47.70 (25.93) -72.60 (16.40)  VAS, 4. Overall/others  FADI* 
 Steroid Inj+Exe  6 weeks  28 28  41.10 (25.93) -79.40 (16.40)  VAS, 4. Overall/others  FADI* 
 Exe  3 months  28 28  31.20 (25.40) -78.70 (21.17)  VAS, 4. Overall/others  FADI* 
 Steroid Inj+Exe  3 months  28 28  29.20 (21.17) -84.00 (21.17)  VAS, 4. Overall/others  FADI* 
Yan,  
2014 
  ESWT+Orth   1 month   51    3.14 (1.61)    VAS, 3. Activity    
 ESWT  1 month  53   3.78 (1.64)   VAS, 3. Activity   
 Orthoses  1 month  49   3.12 (1.71)   VAS, 3. Activity   
 ESWT+Orth  3 months  51   1.95 (1.43)   VAS, 3. Activity   
 ESWT  3 months  53   3.61 (1.62)   VAS, 3. Activity   
 Orthoses  3 months  49   2.60 (1.46)   VAS, 3. Activity   
Ball,  
2013 
  Steroid Inj   6 weeks   44    31.70 (27.85)    VAS, 4. Overall/others    
 Placebo  6 weeks  19   50.90 (31.40)   VAS, 4. Overall/others   
 Steroid Inj  3 months  37   28.30 (24.85)   VAS, 4. Overall/others   
 Placebo  3 months  18   53.80 (33.80)   VAS, 4. Overall/others   









  ESWT+Exe   3 months   20    1.30 (1.84)    VAS, 2. Morning    
 Exe  3 months  20   1.85 (1.87)   VAS, 2. Morning   
 ESWT+Exe  12 months  20   0.80 (1.47)   VAS, 2. Morning   
 Exe  12 months  20   1.05 (1.82)   VAS, 2. Morning   
Guner,  
2013 
  NSAID Inj+Exe   12 months   31    2.94 (2.04)    VAS, 4. Overall/others    
 Steroid Inj+Exe  12 months  30   3.17 (2.31)   VAS, 4. Overall/others   
Walther,  
2013 
  Placebo   3 weeks   10    46.00 (33.90)    VAS, 4. Overall/others    
 Orthoses  3 weeks  20   17.95 (17.50)   VAS, 4. Overall/others   
Yucel,  
2013 
  Steroid Inj   1 month   20 20  3.70 (1.45) -74.60 (7.89)  VAS, 4. Overall/others  FAOS; ADL Subscale* 
 Orthoses  1 month  20 20  4.65 (1.34) -64.80 (6.32)  VAS, 4. Overall/others  FAOS; ADL Subscale* 
McMillan,  
2012 
  Steroid Inj+Exe   1 month   41 41  34.31 (25.47) -70.73 (26.50)  VAS, 1. First-step  FHSQ; Function Subscale* 
 Exe  1 month  40 40  44.79 (26.39) -68.45 (26.55)  VAS, 1. First-step  FHSQ; Function Subscale* 
 Steroid Inj+Exe  3 months  41 41  30.77 (29.93) -78.66 (23.63)  VAS, 1. First-step  FHSQ; Function Subscale* 
 Exe  3 months  40 40  37.34 (27.25) -77.74 (22.62)  VAS, 1. First-step  FHSQ; Function Subscale* 
Vahdatpour, 
2012 
  ESWT   3 months   20    7.60 (0.70)    NRS, 3. Activity    
 Placebo  3 months  20   4.90 (1.60)   NRS, 3. Activity   
Biswas,  
2011 
  Steroid Inj   1 month   60    1.09 (1.16)    VAS, 4. Overall/others    
 Oral NSAID  1 month  60   4.15 (1.18)   VAS, 4. Overall/others   
 Steroid Inj  2 months  60   1.92 (1.22)   VAS, 4. Overall/others   
 Oral NSAID  2 months  60   5.76 (1.62)   VAS, 4. Overall/others   
Ibrahim, 
2010/2017 
  ESWT   1 month   25 25  0.60 (7.50) 1.20 (0.50)  VAS, 4. Overall/others  R&M  
 Placebo  1 month  25 25  7.60 (2.00) 3.60 (0.50)  VAS, 4. Overall/others  R&M  
 ESWT  3 months  25 25  1.10 (1.50) 1.40 (1.00)  VAS, 4. Overall/others  R&M  
 Placebo  3 months  25 25  7.70 (1.00) 3.20 (1.00)  VAS, 4. Overall/others  R&M  
 ESWT  12 months  25 25  2.30 (2.15) 1.90 (0.75)  VAS, 4. Overall/others  R&M  
 Placebo  12 months  25 25  6.90 (3.20) 2.80 (1.20)  VAS, 4. Overall/others  R&M  
Yucel,  
2010 
  Steroid Inj   3 months   33    1.10 (0.90)    VAS, 4. Overall/others    
 ESWT  3 months  27   1.20 (1.10)   VAS, 4. Overall/others   
Chow,  
2007 
  ESWT   5 weeks   17 17  3.72 (0.69) 8.89 (2.62)  VAS, 4. Overall/others  Total FFI  
 Placebo  5 weeks  14 14  5.71 (1.07) 14.77 (1.72)  VAS, 4. Overall/others  Total FFI  
  Exe   2 weeks   46 46  51.10 (29.10) -72.40 (23.60)  VAS, 1. First-step  FHSQ; Function Subscale* 









 Placebo  2 weeks  46 46  62.50 (29.50) -66.40 (26.20)  VAS, 1. First-step  FHSQ; Function Subscale* 
Kudo,  
2006 
  ESWT   3 months   53    3.90 (3.20)    VAS, 1. First-step    
 Placebo  3 months  52   5.30 (2.70)   VAS, 1. First-step   
Landorf,  
2006 
  Orthoses   3 months   89 89  -71.60 (21.90) -82.95 (21.35)  
FHSQ; Pain Subscale, 4. 
Overall/others* 
FHSQ; Function Subscale* 
 Placebo  3 months  44 44  -63.40 (21.50) -79.70 (22.30)  
FHSQ; Pain Subscale, 4. 
Overall/others* 
FHSQ; Function Subscale* 
 Orthoses  12 months  88 88  -83.45 (19.70) -89.85 (18.40)  
FHSQ; Pain Subscale, 4. 
Overall/others* 
FHSQ; Function Subscale* 
 Placebo  12 months  43 43  -82.30 (18.00) -87.80 (20.60)  
FHSQ; Pain Subscale, 4. 
Overall/others* 
FHSQ; Function Subscale* 
Porter,  
2005 
  Steroid Inj+Exe   3 months   64    1.48 (1.75)    VAS, 2. Morning    
 ESWT+Exe  3 months  61   3.69 (2.00)   VAS, 2. Morning   
 Steroid Inj+Exe  12 months  64   0.84 (1.75)   VAS, 2. Morning   
 ESWT+Exe  12 months  61   0.84 (1.00)   VAS, 2. Morning   
Theodore,  
2004 
  ESWT   6 weeks   72    4.60 (3.10)    VAS, 1. First-step    
 Placebo  6 weeks  71   5.00 (3.00)   VAS, 1. First-step   
 ESWT  3 months  73   3.40 (2.70)   VAS, 1. First-step   
 Placebo  3 months  73   4.10 (3.10)   VAS, 1. First-step   
Haake,  
2003 
  ESWT   6 weeks   129    5.20 (3.10)    VNRS, 2. Morning    
 Placebo  6 weeks  131   4.90 (3.10)   VNRS, 2. Morning   
 ESWT  3 months  127   4.00 (3.20)   VNRS, 2. Morning   
 Placebo  3 months  129   4.50 (3.40)   VNRS, 2. Morning   
 ESWT  12 months  112   1.50 (2.60)   VNRS, 2. Morning   
 Placebo  12 months  114   1.70 (2.40)   VNRS, 2. Morning   
Rompe,  
2003 
  ESWT   12 months   16 16  1.50 (1.70) -90.40 (8.30)  VAS, 1. First-step  
AOFAS Ankle-Hindfoot 
Scale* 





  ESWT   6 weeks   80 80  52.80 (34.50) -65.60 (18.70)  VAS, 2. Morning  Maryland Foot Score* 
 Placebo  6 weeks  81 81  47.40 (34.20) -66.60 (17.60)  VAS, 2. Morning  Maryland Foot Score* 
 ESWT  3 months  79 79  48.80 (35.40) -69.90 (20.00)  VAS, 2. Morning  Maryland Foot Score* 







 Placebo  3 months  81 81  44.40 (34.20) -67.20 (20.20)  VAS, 2. Morning  Maryland Foot Score* 
Crawford,  
1999 
  Steroid Inj   1 month   27    2.90 (2.50)    VAS, 4. Overall/others    
 Placebo  1 month  27   4.00 (2.90)   VAS, 4. Overall/others   
 Steroid Inj  3 months  27   3.60 (2.80)   VAS, 4. Overall/others   
  Placebo   3 months   27     3.70 (3.30)     VAS, 4. Overall/others    
 
Abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orth= Extracorporeal shockwave therapy combined with orthoses, 
Exe=exercise, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, 
Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise, n_pain= number of participants at follow-up for pain outcomes, n_function= 
number of participants at follow-up for function outcomes, SD= standard deviation, VAS=visual analogue scale, NRS=numerical rating scale, FHSQ=foot health status questionnaire, VNRS=verbal numerical rating 
scale, FFI=foot function index, AOFAS=American orthopaedic foot and ankle society, FAAM=foot and ankle ability measure, R&M=Roles and Maudsley score, FADI=foot and ankle disability index, FAOS=foot and 
ankle outcome score, ADL=activities of daily living. 
 
* Direction of scale reversed by multiplying mean outcome values by -1 (to ensure all outcomes are interpreted with lower values indicative of improvements in pain or functional disability) 
  







PHP NMA Appendix II 
Table 1: Summary of Findings from Studies that were not included in the network meta-analysis 
Treatment Comparison Trials/ 
Population 
Estimates of treatment effects Comment/quality of 
evidence Pain Function 














Short term: evidence not available in 8 trials. 2 trials, found ESWT statistically significantly superior to 
placebo, with mean resting heel pain (VAS) of 4.49 compared to 15.23 (p† < 0.01) (t=6 weeks)/ 6.0 
compared to 8.3 (note: figures estimated from graphs) (p† < 0.0001) (t=4 weeks). 3rd trial found no 
statistically significant difference between ESWT and placebo, with mean change in heel pain compared 
to baseline (visual analogue scale) of -2.23 compared to -2.12 (p† = 0.79, two-sided) (t=4 weeks) 
 
Medium term: evidence not available in 4 trials.  
3 trials found no statistically significant difference between ESWT and placebo, e.g., % success rate* for 
first steps pain (VAS) 60.80% compared to 48.31%/ 37% compared to 36% (t=3 months) 
4 trials found ESWT statistically significantly better than placebo, e.g., mean change in heel pain 
compared to baseline (VAS) of -3.39 compared to -1.78 (p† < 0.001, two-sided) (t=3 months) and mean 
heel pain (VAS) of 3.43 compared to 4.28 (p† = 0.014) (t=3 months)/ 4.0 compared to 8.5 (note: figures 
estimated from graphs) (p† < 0.0001) (t=3 months). *Dichotomous outcomes: % success rate* of 50.4% 
compared to 36.4% (p† = 0.0136, one-sided) (t=3 months) 
 
*success rate defined by >60% decrease in visual analogue score compared to baseline 
 
Long term: evidence not available in 4 trials: Rompe 1996 did not report placebo outcome and p value 
not reported so cannot compare. 
2 trials found no statistically significant difference between ESWT and placebo e.g., mean change in pain 
(VAS); ESWT, -28.25 (26.06); placebo, -1.78 (44.42) (t=6 months) 
3 trials found ESWT better than placebo, with e.g., % success rate* of 61.60% compared to 47.46% (p† = 
0.0144, one-sided) (t=12 months); mean morning heel pain (VAS) of 1.41 compared to 3.54 (t=12 
months)/ 1.5 (1.7) compared to 4.4 (1.7) (p† < 0.0001) (t=12 months) and 3.3 (0.8) compared to 4.7 (0.8) 
(t=12 months) 
Short term: No evidence 
 
Medium term: No evidence in 9 trials 
2 trials found ESWT to be better than placebo. E.g., % “excellent” 
or “good” (RMS) of 58.40% compared to 41.52% / 60.8% 
compared to 37.2% / 60% compared to 40% (t=12 weeks). 
 
1 trial found ESWT better than placebo based on mean values at 
follow up: 90.4 (8.3) compared to 75.4 (17.3) (p† = 0.0211) (t=12 
months) on AOFAAS scale**  
** AOFAAS scale- American Orthopaedic Foot and Ankle Society’s 
Ankle-Hindfoot Scale: higher scores indicate greater functional 
ability 
 
Uncertainty in evidence 
across trials and time 
points. ESWT appears 
better than placebo. 
Trials assessed as mostly 
unclear and high risk of bias 
on assessment.  
 
 
Exercise v ESWT 1 trial: 
$Rompe 2010 
Short term: No evidence  
Medium term: Exercise found to be better than ESWT, mean change in first step pain: -4.5 (2.4) 
compared to -1.8 (2.0) (t=2 months) 
Long term: No statistically significant difference between exercise and ESWT, mean change first step 




Short term: No evidence  
Medium term: Exercise better than ESWT, mean change 
in first step pain: -21.4 (10.6) compared to -6.6 (1.2) (p† < 
0.001, t=2 months) 
Long term: No statistically significant difference between 
exercise and ESWT, mean change first step pain: -29.1 
(12.8) compared to -28.9 (12.3) (p† = 0.950, t=15 months) 
Exercise appears to confer 
more benefits compared to 
ESWT in the medium term. 
Beneficial effects was not 
sustained in the longer 
term? 
Uncertain evidence from 
only 1 trial 







Unclear risk of bias on most 
ROB items.  






Short term: 1 trial found no difference the mean first step pain score among for custom orthosis, 3.4; 
prefabricated orthosis, 3.9; placebo, 3.6. (p† < 0.65; t=4 weeks)  
Medium term: the 2 trials found no difference between custom orthosis and prefabricated orthosis. E.g 
mean first steps pain: custom orthosis, 2.6; prefabricated orthosis, 2.5; placebo, 2.9 / mean change of 
5.3 in both groups (t=3 months). 
Long term: No evidence found. 
Evidence from a single trial:  
Short term: No statistically significant difference between 
custom, 62.0 and prefabricated 67.4 or placebo 59.4 orthosis 
(t=4 weeks). 
Medium term: No statistically significant difference between 
custom, 57.2 and prefabricated 65.1 or placebo 62.4 (p† < 0.77, 
t=12 weeks). 
Long term: No evidence 
No difference between 
custom or prefabricated 
orthosis.  
Agrees with evidence from 
network. 
Unclear risk of bias on 
assessment. 
Exercise + ESWT + 
prefabricated orthosis v 
ESWT + prefabricated 
orthosis 
1 trial:  
$Rompe 2015 
Short term: No evidence  
Medium term: ESWT + prefabricated orthosis better with exercise than without exercise. Mean change 
of -4.0 (1.5) compared to -1.8 (2.0) (p† < 0.001, t=2 months) 
Long term: Differences were not statistically significant at t=24 months. Mean change for first step pain: 
-5.1 (2.5) compared to -4.2 (2.5) (p† < 0.05) 
Short term: No evidence  
Medium term: ESWT + prefabricated orthosis better with 
exercise than without exercise. Mean change of -20.1 (7.8) 
compared to -12.2 (6.3) (p† < 0.001, t=2 months) 
Long term: ESWT + prefabricated orthosis better with exercise 
than without exercise at t=24 months. Mean change : -35.8 (11.0) 
compared to -27.6 (13.8) (p† < 0.01) . 
Uncertain evidence from 
only 1 trial 
Unclear/low risk of bias. 
Exercise + custom 
orthosis v exercise + 
prefabricated orthosis v 
exercise 
1 trial:  
 
Pfeffer 1999 
Short term: No evidence  
Medium term: No statistically significantly difference between the interventions (p† < 0.35) mean 
change (95% confidence interval) for pain compared to baseline: exercise + custom orthosis, -19.0 (-29.2, 
-8.7); exercise + prefabricated orthosis, -23.3 (-27.9, -18.6); exercise, -15.8 (-26.4, -5.1) (t=2 months) 
Long term: No evidence 
No evidence for function in short, medium or long term follow 
up  
Uncertain evidence from 
only 1 trial. 
Unclear/high risk of bias 
Steroid injection v 
prefabricated orthosis v 
steroid injection + 
prefabricated orthosis 
1 trial:  
 
Kriss 2003 
Short term: Based on mean change in heel pain (VAS) compared to baseline; steroid injection, -65.3 
(23.7) appears better than steroid injection + prefabricated orthosis, -49.3 (31.4) or prefabricated 
orthosis alone -20.3 (26.1); (p† < 0.001, t=4 weeks) 
 
Medium term: Based on mean change in heel pain (VAS) compared to baseline; steroid injection, -61.7 
(28.2); appears better than steroid injection + prefabricated orthosis, -51.4 (31.1) or prefabricated 
orthosis alone -38.6 (30.6); (p† < 0.05, t=12 weeks) 
 
Long term: No statistically significant difference (p† = 0.10) between the three interventions in mean 
change (standard deviation) in heel pain compared to baseline (visual analogue score); steroid injection, 
-63.7 (31.4); prefabricated orthosis, -50.6 (28.6); steroid injection + prefabricated orthosis, -61.3 (27.2) 
(t=6 months) 
No evidence for function in short, medium or long term follow 
up 
For pain only, addition of 
prefabricated orthosis 
does not confer benefits on 
pain reduction.  
Uncertain evidence from 
only 1 trial. 
Mostly unclear/high risk of 
bias on assessment. 
† p value testing for a difference between three treatment groups (in mean change from baseline). Statistical significance level not declared. 
$ mean change (standard deviation) in total Foot Function Index sum score compared to baseline 
  

























Intervention description & dose / 
No of sessions/ Duration of 
treatment :  
Control description & dose / 
No of sessions/ Treatment 
duration: 
Delivered by? Comments:  













Unclear Exercise:  
Plantar fascia stretching with 
Ten second hold and repeat 10 
times x 3/ day 
Duration of treatment: Unclear 
Exercise: 
Achilles tendon stretching: 
with Ten second hold and 




Wrong outcome data (only change 
scores presented, and no baseline 
outcomes). 
Both groups received over the 
counter insoles, a 3-week course of 
NSAIDS and an educational video 






> 6 months,  
50 51.8± 9.1 
52.7± 7.6 
60 Type of shockwave? appliction 
of 1 000 pulses under local 
anaesthetic (5ml of 2% 
prilocaine) 
Placebo:  
Sham ESWT with injection 
of local anaesthetic only  
 Unclear Wrong intervention. Classified not 
to be clinically like the ESWT 
interventions? 
Patients in both groups were 
allowed to take analgesic 
medication (Paracetamol 500 mg ) 









> 6 months 
failed previous 
treatments 
252 52.4± 12 
52±10.5 
102 ESWT: 3 applications of 2 000 
waves to the point of maximal 
tenderness at 0.16J/mm2 over 6 
wks 
Placebo: Sham ESWT, 3 
applications over 6 wks 
Orthopaedic surgeon 
or podiatrist 
Wrong outcome data (only useful 












Unclear ESWT:   
3 applications of ESWT 2 000 
waves to the point of maximal 
tenderness at 0.25 mJ/mm2 over 
3 weeks 
Placebo: Sham ESWT. 3 
sessions over 3 wks 
Unclear 
 
Wrong outcome data (only useful 
outcome data for extraction was for 
binary function). 










> 6 months 
failed previous 
treatment 
40 53.9± 12.5 
58.9± 10.9 
50 ESWT: 3 applications of ESWT 
2 000 waves to the point of 
maximal tenderness at 0.25 
mJ/mm2 over 3 weeks 
Placebo: Sham ESWT. 3 
sessions over 3 wks 
Unclear Wrong outcome data (only change 
scores presented, and no measure of 
variability). All: Pts allowed up to 







pain > 3 
months, 
32 NR NR ESWT: 3 applications of ESWT 
2 000 waves, 6Hz and pressure 
of 3 bar to the point of maximal 
Placebo/Usual care: 10 
sessions of Physiotherapy 
incorporating Ultrasound 
ESWT by Physician 
Usual care by 
Physiotherapist 
Early results of Grecco 2013. 
All: Stretching for the calf and 
plantar fascia at home 









tenderness at 0.25 mJ/mm2 over 
3 weeks 
(1Hz, intensity 1.2 W/cm2) 
and stretching over 5wks 
Martin 
2001 
USA? Unclear Plantar fasciitis 255 47±13 
48±11 
20 (median) custom orthoses:  





Podiatrist Wrong outcome data (only change 
scores presented, and no measure of 
variability). 
All: Taping for 2 weeks using a 
Low Dye technique 
Ogden 
2004 






293 Unclear NR ESWT:  
Electrohydraulic 100 graded 
shocks (14 to 18 kV; 0.12 to 
0.22 
mJ/mm2) followed by 1400 
shocks at 18 kV (0.22 mJ/mm2) 
for a total of 1500 shocks, 
applied at 2 Hz. Total energy at 
324.25 J. 
 





NR Wrong outcome data (only point 
estimates reported, without a 
measure of variability). 
All:  
Anaesthesia with lidocaine prior to 
procedure 
Self-treatment with over-the-
counter analgesics or 
anti-inflammatory medications was 
permitted and documented 
Porter 
2002 




50/94?  Exercise: Sustained stretching 
of Achilles tendon 3x daily, 3 
minutes for 17 weeks following 
1 instruction session by 
physiotherapist 
Exercise:  
Intermittent stretching of 
Achilles tendon 2x daily, 20 
second intervals for 3 
minutes, over 17 weeks. 
physiotherapist 
 
Wrong interventions (too similar to 
separate into different nodes). 





Outpatient Plantar fasciitis 
Inferior heel 









12 repetitions, 3 sets of high 
load strength training. 
Increasing load, with reducing 
no. of reps over 13 weeks 
Exercise:  
10 Stretching repetitions 3x 
per day, for 13 weeks 
physiotherapist 
 
Wrong interventions (too similar to 
separate into different nodes). 
 All: information & advice for 
home exercise plus gel heel inserts 
Rome    
2004 






median 26 Orthoses:  
Functional foot orthoses, made 
of ethyl venyl acetate to achieve 
weight bearing realignment of 
foot and lower limb, 
Orthoses 
Accommodative foot 
orthoses, made of low-
density ethyl venyl acetate; 




Wrong interventions (too similar to 
separate into different nodes). 
All: written and graphic 
information about stretching 
programme 







redistribution of load, shock 
absorption in gait over 8wks 
padding, shock absorption 

















3 applications of 1000 impulses 
of 0.06mJ/mm, radius 1.5-2cm 
over 3 wks. 
Placebo: 3 applications of 
Sham ESWT over 3 wks 
NR 
 
Wrong outcome data (only point 
estimates reported, without a 
measure of variability). 





Outpatient chronic plantar 
fasciitis 
moderate-severe 












65-74  ESWT 
3 applications of 2000 impulses 
of 0.09mJ/mm2 plus local 
anaesthetic over 3 weeks. 
Placebo:  
3 applications of sham 
EWST, without local 
anaesthetic in 3 weeks 
physician Wrong outcome data (only change 
scores presented (mean and 95% 
confidence interval). 









weeks; NRS >6;  
102 53.1±NR 
49.8±NR 
~3.8 Exercise: plantar fascia specific 
stretching: 10 exercise 
repetitions at 10 sec hold 
interval 3 times daily. 1 
instruction session, contacted 
by phone every 2 weeks for 8 
wks 
ESWT: 3 Sham shockwave 
device for 3 weeks 
physician Wrong outcome data (only change 
scores presented (mean and 
standard deviation). 





Outpatient chronic plantar 
heel pain, >12 





70 - 78  Exercise + ESWT: Plantar 
fascia specific stretching (10 
exercise repetitions at 10 sec 
hold interval 3 times daily) + 
ESWT: 3 applications of 
2000 pulses, 0.16mj/mm2 
over 3 wks. 
physician 
 
Wrong outcome data (only change 
scores presented (mean and 
standard deviation). 









EWST 2000 pulses, 
0.16mj/mm2 
1 instruction session, contacted 
by phone every 2 weeks for 8 
wks. 
All: Rescue pain medication. Heel 
pads and advice to continue 
activities as normal. 
Speed 
2003 
England Outpatient Plantar fasciitis 
(unilateral); > 
3mths 
88 51.7± NR 
52.5± NR 
60?  ESWT: 
3 applications of 
Electromagnetic 1500 pulses at 
0.12 mJ/mm2  over 8 weeks. 
Placebo: 3 applications of 
Sham ESWT with deflated 
treatment minimal energy 





Couldn’t extract any useful 
outcome data. 










At least 6 mth 
history, with at 




103 50.46? 96? ESWT:  
Up to 3 applications of 2000 
shockwaves over 4 weeks 
Placebo: Sham ESWT 




Couldn’t extract any useful 
outcome data (given in the form of 
graphs only). 
Treatments carried out with or 




Brazil Unclear Plantar fasciitis 
(bilateral) >30 
days 
83 45.2± 12 
44.5± 11.5 
73.2 Exercise: daily stretching & bi-
weekly strengthening exercises  
for 8 wks 
Exercise 
Foot exercises (daily 
stretching exercises only). 
for 8 weeks. 
Physiotherapist (for 
bi-weekly sessions. 
Wrong interventions (too similar to 
separate into different nodes). 
Kriss 
2003 
England Unclear  unilateral heel 
pain. anti-
inflamm med 
stopped 6 weeks 
before 
inclusion. 








Wrong outcome data (only change 
scores presented (mean and 
standard deviation). 
Intervention 3: combination of 
steroid injection and orthoses 
(exactly as in interventions 1 and 2) 
Liang 
2007 
Taiwan Outpatient Plantar fasciitis. 








3 applications of Low intensity 
piezoelectric shockwave of 
2000 impulses at 0.12 mJ/mm2 
over 2 weeks. 
ESWT 
High intensity piezoelectric 
shockwave  
3 applications of Low 
intensity piezoelectric 




Wrong interventions (too similar to 
separate into different nodes). 
 










impulses at 0.56 mJ/mm2 





Unclear Plantar fasciitis/ 





score of 3 or 4  
39 45±NR 
52±NR 
NR ESWT: 3 applications of 2000 
Shockwave impulses 
(freq=10Hz), 0.20 mJ/mm2 over 
2 weeks 
ESWT:  
3 applications of 2000 
Shockwave impulses 
(freq=10Hz), 0.17 mJ/mm2 
over 2 weeks 
Physician  Wrong outcome data (only point 
estimates reported, without a 
measure of variability). 
Malay 
2006 
US Unclear Plantar fasciitis 
(proximal) 




score > 5  
172 50.8±10.1 
52.1±11.1 
130 ESWT: 1 application of 3800 
shockwaves (150 shock/min). 
for 25 minutes. 





Wrong outcome data (only change 




USA? Unclear Proximal 
plantar fasciitis 
236 48.5± NR 
49.5±NR 
unclear custom orthoses:  
polypropylene neutral orthosis  
prefabricated orthoses: 
silicone heel pad 
NR Wrong outcome data (only change 
scores presented (mean and 
standard deviation). 
Int 3: pre-fabricated orthoses; 
rubber heel cup Int 4: pre-fabricated 
orthoses; a felt insert 




USA Unclear Plantar heel 
pain/plantar 
fasciitis < 1 yr 
77 47.1± NR 
51.3± NR 
21 custom orthoses: Standard 
prescription with 
accommodations for body 
stature, foot 
data, first-ray and ankle 
function worn for 12 wks 
 
prefabricated orthoses: full 
foot–length, triplanar 
orthotic footbed with a 15-






Wrong outcome data (only point 
estimates reported, without a 
measure of variability). 
Group 3: sham orthoses:  
fabricated by certified pedorthist. 
All treated with removable 
longitudinal and metatarsal pads for 
the 7-14 day period before orthosis 
arrival plus standardized athletic 
shoes and standardized foot self-
care advice 




















referral to our 
hospital. 
60 NR ~34 ESWT: 
6 applications of 1200 shocks 
with a frequency of 120 
shocks/min; at varied energy 
density from 0.03 to 0.04 
mJ/mm2 over 8-9weeks. 
ESWT:  
6 applications of 1200 
shocks with a frequency of 
120 shocks/min; at  0 
mJ/mm2 energy density? 
NR 
 
Wrong outcome data (only point 
estimates reported, without a 
measure of variability). 




         Couldn’t extract any useful 






Unclear Plantar fasciitis 25 51.9±11.9 
51.7±14.3 
113.2 ESWT:  
3 applications of 500 
Shockwave impulses for the 1st 
session, then 2000 shock waves 
in two further sessions, at 3 
days’ intervals. Energy density 
was 0.16 mJ/mm2.  
Placebo: Sham ESWT. As 
intervention group but 
energy density reduced 
almost to zero 
Orthopaedic surgeon Wrong outcome data (only change 










142 47.5 ± 11.5 
47.2 ± 12.4 
NR Prefabricated orthoses: made from 
95% EVA, worn for 8 weeks.  
Custom orthoses: 
Made from 95% EVA worn for 
8 weeks 
Principal Investigator Wrong interventions (too similar to 
separate into different nodes). 
NR: Not Reported 
?: Data given but unclear/could not be verified 
 
 
